Management consultancy in FR. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical indicative ranges based on public filings. This is not an asking price or confirmation that the company is for sale.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Continue privately and connect your accounting data to make the graph more accurate.
Continue as ownerTrack the buying status below. If the owner opens a process, you can request a conversation and review the details before making an offer.
View buying statusYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The valuation for NEFTYS.PHARMA combines official public company figures with Upswitch sector calibration. The owner can sharpen it with their own figures and context into a full, defensible valuation curve.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
NEFTYS.PHARMA is a management consultancy based in France. The company was founded in 2003, incorporated as a 5710.
NEFTYS.PHARMA is listed in French National Business Register (RNE/INPI) under registry number 444653794. The public employee band is 12, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 70.22 cluster, public-record data is filed annually via the national company registry.
Across the 2017-2024 window revenue has more than doubled, moving from €1,150,200 to €4,598,795.
An indicative valuation band is available for NEFTYS.PHARMA, based on filed company accounts. A free account lets the visitor refine it with current data and build a five-year outlook.
The most recent annual filing covers 2024 (period end 2024-12-31).
If you are researching NEFTYS.PHARMA for acquisition, investment, or due-diligence purposes, this page consolidates its firmographics, multi-year filings, and an indicative valuation into a single, citation-ready view.
Public regulator-filed figures across 8 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 202431 Dec 2024 | €4,598,795 | - | €163,538,841 | €94,131,868 | - |
| 202331 Dec 2023 | €3,399,998 | - | €165,872,974 | €93,127,481 | - |
| 202231 Dec 2022 | €3,899,998 | - | €160,065,740 | €90,012,835 | - |
| 202131 Dec 2021 | €1,650,003 | - | €109,789,350 |
NEFTYS.PHARMA was founded in 2003 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
NEFTYS.PHARMA is registered under NACE 70.22: NACE 70.22. That places the business within the French cluster for this activity.
This page shows a rounded, automated indicative range generated by Upswitch from official registry facts, public company-size information, filed accounts where available, and governed sector benchmarks. The evidence basis is labelled beside the graph. It is not a certified or statutory valuation, sale price, offer, recommendation, or financial, investment, tax or legal advice. Figures for NEFTYS.PHARMA may be incomplete or inaccurate and must not be relied upon for any transaction; a precise valuation needs owner- or advisor-supplied data.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
| €60,424,566 |
| - |
| 202030 Jun 2020 | €2,401,082 | - | €65,768,175 | €47,401,137 | - |
| 201930 Jun 2019 | €1,747,180 | - | €54,840,876 | €43,471,072 | - |
| 201830 Jun 2018 | €1,384,034 | - | €46,142,501 | €40,002,219 | - |
| 201730 Jun 2017 | €1,150,200 | - | €44,709,122 | €36,915,327 | - |
The most recently filed annual accounts cover fiscal year 2024 (period end 2024-12-31), publicly available via French National Business Register (RNE/INPI).
